synthetic oligonucleotides

The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.

The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.

The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.

The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.

The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.

A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.

Illumina, Twist Bioscience, and DNA Script are among the private sector collaborators of the groups receiving funds to develop technology platforms.

The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.

LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.